{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:53:20Z","timestamp":1776153200700,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.blre.2007.03.001","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T11:54:13Z","timestamp":1179921253000},"page":"201-216","source":"Crossref","is-referenced-by-count":73,"title":["Peripheral T-cell Lymphomas"],"prefix":"10.1016","volume":"21","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2007.03.001_bib1","series-title":"World Health Organization Classification: Tumours of Hematopoetic and lymphoid Tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.blre.2007.03.001_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/asheducation-2005.1.267","article-title":"Aggressive peripheral T-cell lymphomas (specified and unspecified types)","author":"Savage","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.blre.2007.03.001_bib3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.1991.9.8.1426","article-title":"Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience","volume":"9","author":"Kwak","year":"1991","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2007.03.001_bib4","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib5","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2007.03.001_bib6","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/cncr.20531","article-title":"Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi","volume":"101","author":"Morabito","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.blre.2007.03.001_bib7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.blre.2007.03.001_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Annals of Oncology"},{"issue":"Nov 26","key":"10.1016\/j.blre.2007.03.001_bib9","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","author":"Gallamini","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2007.03.001_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1990.tb02560.x","article-title":"CD30-positive large cell lymphomas (\u2019Ki-1 lymphoma\u2019) are associated with a chromosomal translocation involving 5q35","volume":"74","author":"Mason","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2007.03.001_bib11","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues","first-page":"189","article-title":"Mature T-cell and NK-cell neoplasms","author":"Banks","year":"2001"},{"issue":"5","key":"10.1016\/j.blre.2007.03.001_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1309\/GQ2RLNDWLB9WY6UU","article-title":"Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms","volume":"121","author":"Nascimento","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2007.03.001_bib13","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997;89(11):3909\u201318.","DOI":"10.1182\/blood.V89.11.3909"},{"issue":"5196","key":"10.1016\/j.blre.2007.03.001_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.267.5196.316-b","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non- Hodgkin\u2019s lymphoma [letter]","volume":"267","author":"Morris","year":"1995","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.blre.2007.03.001_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jcp.53.6.445","article-title":"ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination","volume":"53","author":"ten Berge","year":"2000","journal-title":"J Clin Pathol"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib16","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2007.03.001_bib17","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2007.03.001_bib18","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.leu.2403955","article-title":"Natural killer-cell malignancies: diagnosis and treatment","volume":"19","author":"Kwong","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2007.03.001_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2007.03.001_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.blre.2007.03.001_bib21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.3800625","article-title":"Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified","volume":"19","author":"Grogg","year":"2006","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.blre.2007.03.001_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1365-2141.2003.04335.x","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"121","author":"Dogan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2007.03.001_bib23","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues","first-page":"191","article-title":"Mature T-cell and NK neoplasms: Introduction","author":"Jaffe","year":"2001"},{"issue":"13","key":"10.1016\/j.blre.2007.03.001_bib24","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2007.03.001_bib25","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":"Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2007.03.001_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1526-9655(11)70265-2","article-title":"Subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Wang","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.blre.2007.03.001_bib27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma: The International NHL Prognostic Factors Project","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.1331","article-title":"ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects\u2013a review","volume":"200","author":"ten Berge","year":"2003","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2003-05-1401","article-title":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2007.03.001_bib30","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2002-05-1352","article-title":"Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL","volume":"103","author":"Tsuchiya","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2007.03.001_bib32","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-03-2068","article-title":"Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma","volume":"64","author":"Niwa","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2007.03.001_bib33","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T\/null cell phenotype [In Process Citation]","volume":"96","author":"Suzuki","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2007.03.001_bib34","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.2004.10.172","article-title":"Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma","volume":"22","author":"Schlette","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2007.03.001_bib35","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1182\/blood.V99.12.4540","article-title":"Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma","volume":"99","author":"ten Berge","year":"2002","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2007.03.001_bib36","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/1078-0432.CCR-04-0269","article-title":"Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes","volume":"10","author":"Martinez-Delgado","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.blre.2007.03.001_bib37","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Martinez-Delgado","year":"2005","journal-title":"Leukemia"},{"issue":"Supp 5","key":"10.1016\/j.blre.2007.03.001_bib38","first-page":"124a","article-title":"Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas","volume":"16","author":"Ballester","year":"2005","journal-title":"Annals of Oncology"},{"issue":"14","key":"10.1016\/j.blre.2007.03.001_bib39","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2007.03.001_bib40","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2007.03.001_bib41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2007.03.001_bib42","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.blre.2007.03.001_bib43","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.V83.9.2451.2451","article-title":"P-glycoprotein expression and function in circulating blood cells from normal volunteers","volume":"83","author":"Klimecki","year":"1994","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib44","doi-asserted-by":"crossref","first-page":"811a","DOI":"10.1182\/blood.V106.11.811.811","article-title":"The International PTCL Project Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. Session Type: Oral Session","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2007.03.001_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1368-8375(98)80014-6","article-title":"Primary CD30-positive anaplastic large cell lymphoma of the lip","volume":"34","author":"Chim","year":"1998","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0360-3016(02)02916-4","article-title":"Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality","volume":"54","author":"Cheung","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.blre.2007.03.001_bib47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdh143","article-title":"Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan","volume":"15","author":"You","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2007.03.001_bib49","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2007.03.001_bib50","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.blre.2007.03.001_bib51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2007.03.001_bib52","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib53","first-page":"2710a","article-title":"Autologous Stem Cell Transplantation in Induction Failure Patients with Peripheral T-cell Lymphoma: The GEL\/TAMO Experience","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2007.03.001_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.thj.6200359","article-title":"Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study","volume":"5","author":"Reimer","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.blre.2007.03.001_bib55","doi-asserted-by":"crossref","unstructured":"Reimer P, Rudiger T, Schertlin E, Weissinger F, Einsele H, K. M-HH, et al. Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-cell Lymphomas. A Prospective Multicenter Study. Blood 2005;106(11):2074a.","DOI":"10.1182\/blood.V106.11.2074.2074"},{"issue":"10","key":"10.1016\/j.blre.2007.03.001_bib56","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2007.03.001_bib57","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.blre.2007.03.001_bib58","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.blre.2007.03.001_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib60","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2007.03.001_bib61","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib62","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib64","doi-asserted-by":"crossref","first-page":"2641a","DOI":"10.1182\/blood.V104.11.2641.2641","article-title":"Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relpased\/Refractory T-cell non-Hodkin\u2019s Lympoma","volume":"104","author":"Dang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.03.001_bib65","doi-asserted-by":"crossref","unstructured":"Piekarz RL, Frye R, Turner M, Wright J, Allen LS, Smith S, et al. Responses and Molecular markers in patients with peripheral t-cell lymphoma treated on a phase II trial of depsipeptide, FK228. 2005;(3061a).","DOI":"10.1200\/jco.2005.23.16_suppl.3061"},{"issue":"8","key":"10.1016\/j.blre.2007.03.001_bib66","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib67","doi-asserted-by":"crossref","first-page":"2640a","DOI":"10.1182\/blood.V104.11.2640.2640","article-title":"Combination chemo-immunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin is an effective first-line regimen in peripheral T-cell lymphoma","volume":"104","author":"Weidmann","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2007.03.001_bib68","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.pas.0000213334.40358.0e","article-title":"Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma","volume":"31","author":"Rodig","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib69","doi-asserted-by":"crossref","first-page":"2637a","DOI":"10.1182\/blood.V104.11.2637.2637","article-title":"SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma","volume":"104","author":"Forero-Torres","year":"2004","journal-title":"Blood"},{"issue":"104","key":"10.1016\/j.blre.2007.03.001_bib70","doi-asserted-by":"crossref","first-page":"2636a","DOI":"10.1182\/blood.V104.11.2636.2636","article-title":"Phase I\/II Open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory\/relapsed CD30 positive lypmphoma","volume":"104","author":"Ansell","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2007.03.001_bib71","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/1042819031000099625","article-title":"ALK a novel lymphoma-associated tumor antigen for vaccination strategies","volume":"44","author":"Passoni","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2007.03.001_bib72","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.2002.20.5.1426","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"20","author":"Mounier","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2007.03.001_bib73","doi-asserted-by":"crossref","first-page":"2486a","DOI":"10.1182\/blood.V104.11.2486.2486","article-title":"CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL","volume":"104","author":"Czuczman","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2007.03.001_bib74","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/annonc\/mdh409","article-title":"Towards understanding the peripheral T-cell lymphomas","volume":"15","author":"Armitage","year":"2004","journal-title":"Ann Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X07000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X07000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T07:39:00Z","timestamp":1587541140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X07000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0268960X07000239"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2007.03.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}